^
    Back
    Association details:
    Biomarker:EGFR L858R
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

    Excerpt:
    ...- Prior genotyping positive for an EGFR activating mutation (L858R, exon 19 deletion, G719X, L861Q)...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

    Published date:
    12/29/2020
    Excerpt:
    Eligible pts had advanced EGFR-mutant NSCLC with prior TKI exposure….objective response rate (ORR) was 100% and median progression-free survival (PFS) was 16.8 months….48% exon 19 del and 37% L858R, median 1 prior line of therapy.
    DOI:
    10.1158/1078-0432.CCR-20-4084